415 related articles for article (PubMed ID: 29271914)
1. Hepatitis C Virus: Viral Quasispecies and Genotypes.
Tsukiyama-Kohara K; Kohara M
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271914
[TBL] [Abstract][Full Text] [Related]
2. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
[TBL] [Abstract][Full Text] [Related]
3. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of hepatitis C virus in liver disease patients in Botswana: a retrospective cross-sectional study.
Bhebhe L; Anderson M; Souda S; Choga WT; Zumbika E; Shaver ZM; Mbangiwa T; Phinius BB; Banda CC; Melamu P; Musonda RM; Essex M; Blackard JT; Moyo S; Gaseitsiwe S
BMC Infect Dis; 2019 Oct; 19(1):875. PubMed ID: 31640596
[TBL] [Abstract][Full Text] [Related]
5. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.
Bagaglio S; Uberti-Foppa C; Morsica G
Drugs; 2017 Jul; 77(10):1043-1055. PubMed ID: 28497432
[TBL] [Abstract][Full Text] [Related]
6. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus.
Li DK; Chung RT
Methods Mol Biol; 2019; 1911():3-32. PubMed ID: 30593615
[TBL] [Abstract][Full Text] [Related]
7. Therapy Implications of Hepatitis C Virus Genetic Diversity.
Martinez MA; Franco S
Viruses; 2020 Dec; 13(1):. PubMed ID: 33383891
[TBL] [Abstract][Full Text] [Related]
8. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.
Echeverría N; Betancour G; Gámbaro F; Hernández N; López P; Chiodi D; Sánchez A; Boschi S; Fajardo A; Sóñora M; Moratorio G; Cristina J; Moreno P
Virus Res; 2016 Sep; 223():140-6. PubMed ID: 27449600
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of HCV antiviral drug resistance.
Welsch C; Zeuzem S
Curr Opin Virol; 2012 Oct; 2(5):651-5. PubMed ID: 23006585
[TBL] [Abstract][Full Text] [Related]
10. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
11. HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A case study.
Bartolini B; Selleri M; Garbuglia AR; Giombini E; Taibi C; Lionetti R; D'Offizi G; Capobianchi MR
J Clin Virol; 2015 Nov; 72():60-5. PubMed ID: 26418073
[TBL] [Abstract][Full Text] [Related]
12. HCV genetic variability: from quasispecies evolution to genotype classification.
Argentini C; Genovese D; Dettori S; Rapicetta M
Future Microbiol; 2009 Apr; 4(3):359-73. PubMed ID: 19327119
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C Virus and Interferon-Free Antiviral Therapeutics Revolution: Implications for Pakistan.
Afzal MS
Viral Immunol; 2017 May; 30(4):252-257. PubMed ID: 28118096
[TBL] [Abstract][Full Text] [Related]
14. Use of whole genome sequencing in the Dutch Acute HCV in HIV study: focus on transmitted antiviral resistance.
Christiansen MT; Hullegie SJ; Schutten M; Einer-Jensen K; Tutill HJ; Breuer J; Rijnders BJA
Clin Microbiol Infect; 2017 Feb; 23(2):123.e1-123.e4. PubMed ID: 27693529
[TBL] [Abstract][Full Text] [Related]
15. Development and Validation of a Template-Independent Next-Generation Sequencing Assay for Detecting Low-Level Resistance-Associated Variants of Hepatitis C Virus.
Wei B; Kang J; Kibukawa M; Chen L; Qiu P; Lahser F; Marton M; Levitan D
J Mol Diagn; 2016 Sep; 18(5):643-656. PubMed ID: 27393904
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
Cristina J; del Pilar Moreno M; Moratorio G
Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.
Chayama K; Tsubota A; Kobayashi M; Okamoto K; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Kumada H
Hepatology; 1997 Mar; 25(3):745-9. PubMed ID: 9049229
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus infection: Are there still specific problems with genotype 3?
Gondeau C; Pageaux GP; Larrey D
World J Gastroenterol; 2015 Nov; 21(42):12101-13. PubMed ID: 26576095
[TBL] [Abstract][Full Text] [Related]
19. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.
Wyles DL; Gutierrez JA
J Viral Hepat; 2014 Apr; 21(4):229-40. PubMed ID: 24597691
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]